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Age-related muscle decline is associated with functional impairment of satellite cells (SCs). Conflicting data
suggest dysregulation of cell-extrinsic or -intrinsic factors can independently contribute to such impairment.
Here, we emphasize the importance of identifying nodes that integrate these factors into feed-forward
circuits, which could provide targets for therapeutic intervention.Satellite cells (SCs) are tissue-resident
muscle stem cells required for postnatal
tissue growth and repair through replace-
ment of compromised myofibers. Recent
studies have revealed that progressive
impairment of SC function correlates
with the decline of muscle regenerative
potential typically observed during
mammalian aging. This functional ex-
haustion of regenerative potential has
been proposed to arise from loss of integ-
rity of the regulatory networks that main-
tain a quiescent pool of reserve SCs and
ensure proper transitions between SC
quiescence, activation, and transition
into committed progenitors. Quiescent
SCs are poised to rapidly respond to
microenvironmental cues, such as those
provided by extracellular and cellular
components of the SC niche, and SC
activation occurs as a tightly regulated
event in response to muscle injury. The
coordinated temporospatial interplay be-
tween SCs, differentiated myofibers, and
interstitial cellular components of the SC
niche is therefore essential for maintain-
ing SC number and function throughout
life. Progressive dysregulation of this
interplay during aging is emerging as a
major cause of loss of SC quiescence.
Experiments utilizing parabiotic con-
joining of mice showed that exposure of
aged SCs to a youthful environment is suf-
ficient to restore their regenerative poten-
tial, indicating a critical role of systemic
components in regulating SC function
(Brack et al., 2007; Conboy et al., 2005).
These experiments revealed a previously
unappreciated reversibility of age-associ-
ated impairment of SCs by restoring the
physiological network of extrinsic cuespresent in young organisms. More
recently, work has identified aberrant acti-
vation of several signaling pathways, such
as STAT3, p38, FGF2, and canonical Wnt
signaling, and a reduction of Notch
pathway activity in aged muscles. Inter-
estingly, all of these changes impacted
on the transition of SCs to a progenitor
stage, leading to impaired control of
quiescence and self-renewal (Bernet
et al., 2014; Brack et al., 2007; Chakkala-
kal et al., 2012; Cosgrove et al., 2014;
Price et al., 2014; Tierney et al., 2014).
Elegant studies from the Brack group pro-
vided clear evidence that during aging,
increased FGF2 signaling in the aged
niche can cause SCs to lose quiescence
(Chakkalakal et al., 2012). Subsequent
studies linked altered FGF2 signaling
with constitutive, aberrant activation of
the p38 MAPK pathway, leading to
impaired self-renewal of aged SCs (Ber-
net et al., 2014; Cosgrove et al., 2014).
Intriguingly, these two studies performed
transplantation assays of aged SCs into
younger mice and showed that the aged
SC phenotype could not be rescued by
a young environment—a finding seem-
ingly in conflict with the conclusions
from parabiosis experiments (Brack
et al., 2007; Conboy et al., 2005). While
this discrepancy may be due to the
different experimental settings and as-
says utilized, we argue that transplanted
SCs might be ‘‘primed’’ by the aged
organism of derivation and adopt a
constitutive, refractory phenotype upon
manipulations, such as isolation and
transplantation, that are known to
artificially activate SCs. Thus, the cell-
autonomous resistance to youthful cuesCell Stem Ceobserved after transplantation of aged
SCs could arise from changes that cannot
be erased by exposure to a young
environment.
Such a priming mechanism could be
mediated by epigenetic changes during
aging and in response to extrinsic signals.
Consistently, Liu et al. identified transcrip-
tional and epigenetic signatures of SC
aging, including loss of bivalency at pro-
moters of developmental genes. Bivalent
promoters are simultaneously marked
by activatory and repressory marks
(H3K4me3 and H3K27me3, respectively).
Such promoters are associated with
genes poised to be activated during line-
age commitment in embryonic stem cells
and correlate with stemness in quiescent
SCs (Liu et al., 2013). As such, it is
possible that progressive loss of bivalent
domains compromises quiescence in
aging SCs, and such domains might be
restored by exposure to youthful cues
when SCs are in their native environment.
In contrast, physical procedures, such as
isolation and transplantation that notori-
ously lead to SC activation, might impose
a resistance to external cues and render
these epigenetic changes irreversible.
While cell non-autonomous changes
in the aged SC niche may provide the
initial trigger ultimately leading to epi-
genetic dysregulation and compromised
SC function, identification of nodes that
integrate these disparate cell-intrinsic
and -extrinsic signals to sustain the irre-
versibility of this process might reveal
therapeutic targets for anti-aging inter-
ventions. The finding that pharmacolog-
ical blockade of FGF2, p38, and STAT3
signaling, which are aberrantly activatedll 16, June 4, 2015 ª2015 Elsevier Inc. 585
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(Bernet et al., 2014; Brack et al., 2007;
Chakkalakal et al., 2012; Cosgrove et al.,
2014; Price et al., 2014; Tierney et al.,
2014) indicates that these pathways
control downstream feed-forward circuits
that establish and maintain aging-associ-
ated changes in SCs. Intriguingly, p38 and
STAT3 signaling are essential activators
of skeletal myogenesis and promote
SC differentiation during regeneration
(Price et al., 2014; Tierney et al., 2014),
thereby raising the question of how acti-
vation of these same signaling pathways
can impair SC performance in aged
muscles. One possibility is altered
cellular distribution of activated pathway
components. Presumably, activated sig-
naling components are restricted to
committed progeny of SC in young mus-
cles but become uniformly activated in
all SCs of old mice. Moreover, changes
in the epigenetic landscape in aged
SCs might alter chromatin accessibility
to downstream signaling pathway effec-
tors, thereby modulating transcriptional
output.
The cellular basis underlying the switch
from physiological activation of the p38
and STAT3 pathways in young SCs (i.e.,
by regeneration cues) to age-associated
constitutive activation has not yet been
conclusively demonstrated. One potential
mechanism underlying this switch is the
aberrant levels of inflammatory cytokines
typically observed in aged organisms.
Consistent with extrinsic changes (i.e.,
the cellular components of the niche, the
related secretome, and biomechanical
cues) activating a feed-forward mecha-
nism that amplifies age-related events in
SCs, exposure to biomaterials that mimic
the biomechanical properties of young
muscles can rescue the age-related de-
fects of SCs (Cosgrove et al., 2014). A
second possibility is that shifts in
the heterogeneity of the SC population
during aging underlie this switch in activa-
tion. Consistently, p38 inhibition and
biomechanical cues may only target a
subset of the aged SC compartment and
change the cellular composition of the
SC pool rather than act to reverse the
aged phenotype per se.
As mentioned above, cellular senes-
cence is one process associated with
the functional decline of aged tissues.
While the precise relationship between
cellular senescence and aging has not586 Cell Stem Cell 16, June 4, 2015 ª2015 Ebeen determined, increasing evidence
suggests that senescence can be a ‘‘point
of no return’’ at which aging SCs acquire a
cell-autonomous phenotype that limits
their functional capacity. Of interest, a
recent breakthrough from the Munoz-
Canoves group has identified a number
of senescence-associated features in
SCs isolated from over 2-year-old (geri-
atric) mice. This phenomenon has been
termed ‘‘geroconversion’’ and appears
to be mediated by de-repression of
the cell cycle inhibitor p16 (INK4a)—a
hallmark of cellular senescence (Sousa-
Victor et al., 2014). This evidence sug-
gests that an altered nuclear landscape
in SCs from aged animals might de-
regulate gene expression and even alter
accessibility of chromatin to certain sig-
naling pathways. In this regard, alter-
ations of histone modifications (i.e., the
reduction of genes marked by a ‘‘biva-
lent’’ chromatin) and histone variants de-
tected in aged SCs (Liu et al., 2013) might
alter the physiological response to envi-
ronmental signals. Thus, in addition to
an elevated concentration of upstream
extracellular signals in aged tissues, an
increased or altered sensitivity to pro-dif-
ferentiation cues can further contribute to
the age-related functional exhaustion of
SCs. Interestingly, previous work has
shown that p38 signaling can directly
control chromatin structure by targeting
key components of the chromatin-modi-
fying machinery, including the Polycomb
Repressive Complex (PRC2). Disruption
of PRC2-mediated gene repression leads
to constitutive de-repression of senes-
cence hallmarks, such as p16, and con-
version of aged SCs into senescent cells
in geriatric mice (Sousa-Victor et al.,
2014).
It remains unclear how p38 inhibition
could reverse cell cycle arrest associated
with cellular senescence (Bernet et al.,
2014; Cosgrove et al., 2014), which
was previously considered irreversible.
A potential explanation arises from the
different ages of the mice used in these
studies, with p38 inhibition restoring cell
cycle activity in pre-senescent, but not
senescent, SCs—an effect that has been
widely reported in SCs of young mice.
The emerging relationships between
chromatin structure, signaling pathways,
and their potential impact on the irrevers-
ible impairment of SCs in geriatric mice
deserve future studies.lsevier Inc.Although the decline in the regenerative
potential of aged SCs is well docu-
mented, whether this contributes to
reduced homeostatic maintenance and
progressive reduction in muscle mass in
aged individuals—known as sarcope-
nia—is still a matter of debate. By utilizing
an inducible mouse model to selectively
ablate Pax7+ SCs, the Peterson team
has recently shown that aging-associated
sarcopenia is not affected by depletion of
SCs, thereby underscoring the low turn-
over nature of skeletal muscle and point-
ing to mature myofibers as the direct
cellular targets of this chronic process
(Fry et al., 2015). However, an increase
in fibrosis in aged muscles was observed
in these SC-depleted mice. Thus, while
these findings indicate that SCs are not
directly involved in aged-associated sar-
copenia, they also reveal once again the
contribution of SCs to the niche/signaling
network that regulates muscle homeosta-
sis. This hypothesis is consistent with a
function of SCs not only in tissue repair,
but also as sources and targets of
secreted or cell-contact-mediated sig-
nals for coordinated spatio-temporal
regulation of the regenerative niche.
Further elucidation of the reciprocal inter-
actions between SCs and the other cell
types within the niche will improve our
understanding of skeletal muscle homeo-
stasis and identify novel targets for
pharmacological interventions to counter
age-related muscle loss.
Future Perspectives
The interconnected nature of extrinsic
and intrinsic changes occurring in SCs
during aging suggests that they are both
integral components of a self-amplifying
molecular network triggered by age-asso-
ciated perturbations in the SC niche. It is
likely that this network evolves into a
cell-autonomous and irreversible cause
of SC impairment. Whether this potential
scenario corresponds to geroconversion
will be an interesting matter for future
investigation. Ultimately, elucidating the
molecular and epigenetic determinants
underlying the interplay between extrinsic
and intrinsic factor changes in SCs will
reveal the nodal points in this network,
and such nodes may be amenable to tar-
geted interventions aimed at interrupting
the vicious cycle underlying SC aging.
In this context, a significant challenge
is posed by the intrinsic heterogeneity of
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ment of highly sensitive technologies for
single-cell analyses will enable us to
improve our understanding of SC hetero-
geneity, how SC populations change with
age, andwhat physiological role this plays
in themaintenance of tissue homeostasis.
Intriguingly, SC heterogeneity could not
only be an intrinsic property of the SC
compartment, but may also arise from
microenvironmental cues/gradients to
which SCs are locally exposed within the
tissue. This critical spatial information is
lost upon tissue enzymatic digestion and
cell isolation, limiting our understanding
of SC heterogeneity. The optimization of
strategies to perform 3D tissue imaging
would enable us to monitor SCs in native
tissues, investigate the spatial heteroge-
neity, and shed light on the relationship
between anatomical proximity to specific
cell types and establishment of recip-
rocal functional interactions. These ap-
proaches should be complemented with
multicolor Cre reporters for clonal lineage
tracing in vivo in order to further clarify SC
dynamics in living tissues. Finally, under-standing the degree towhich these animal
models of aging and degenerative dis-
ease recapitulate human conditions is a
major challenge we face. Translational ef-
forts aimed at integrating basic research
with patient-oriented studies in the clinic
could enable addressing these funda-
mental questions and further the develop-
ment of treatments for aging-associated
defects in muscle function.ACKNOWLEDGMENTS
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